https://www.fiercebiotech.com/biotech/roche-axes-carmot-obesity-asset-3-cancer-drugs-rd-clearout
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Jul 24, 2025 - Roche has axed one of the obesity assets from its Carmot buyout months after hyping its potential to drive weight loss past the GLP-1 plateau.
https://www.fiercebiotech.com/biotech/carmot-therapeutics-bags-15m-for-glp-1r-gipr-agonist
Carmot Therapeutics bags $15M for GLP-1R/GIPR agonist | Fierce Biotech
Jan 17, 2018 - Carmot Therapeutics closed a $15 million series B round, which will carry its lead Type 2 diabetes drug, a GLP-1R/GIPR agonist, through clinical proof of...
glp 1rcarmottherapeuticsbags15m